Eli Lilly and Company's results for Q3 2024 reflect a robust performance driven by strong demand for new products, particularly Mounjaro and Zepbound, with a reported revenue of $11.44 billion—an impressive YoY growth of 42% when excluding the olanzapine portfolio divestiture. The company's gross profit margin improved to 81%, aided by increased demand and improved pricing strategies. Despite challenges in production and inventory dynamics recognized in previous quarters, management remains optimistic about growth trajectories heading into 2025, particularly with enhanced guidance for the upcoming quarter. Moreover, significant strategic investments in manufacturing expansions and R&D signal a commitment to long-term growth, alongside a focus on maintaining strong shareholder returns through dividends and share repurchases.